Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 216-223-3 | CAS number: 1530-32-1
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Key value for chemical safety assessment
- Toxic effect type:
- dose-dependent
Effects on fertility
Description of key information
Reproductive toxicity study:
A study is not scientifically necessary and does not need to be conducted, since a pre-natal developmental toxicity study is conducted and is included in the dossier.
Link to relevant study records
- Endpoint:
- screening for reproductive / developmental toxicity
- Data waiving:
- study scientifically not necessary / other information available
- Justification for data waiving:
- the study does not need to be conducted because a pre-natal developmental toxicity study is available
- Endpoint:
- extended one-generation reproductive toxicity - basic test design (Cohorts 1A, and 1B without extension)
- Data waiving:
- study scientifically not necessary / other information available
- Justification for data waiving:
- other:
Referenceopen allclose all
Effect on fertility: via oral route
- Endpoint conclusion:
- no study available
- Quality of whole database:
- Study Scientifically Not Necessary/Waiver
Effect on fertility: via inhalation route
- Endpoint conclusion:
- no study available
Effect on fertility: via dermal route
- Endpoint conclusion:
- no study available
Additional information
Reproductive toxicity study:
A study is scientifically not necessary and does not need to be conducted, since a pre-natal developmental toxicity study is conducted and is included in the dossier.
Effects on developmental toxicity
Description of key information
Developmental toxicity study:
Based on the available data, it was concluded that the test chemical did not show any adverse effects on maternal reproductive/developmental toxicity and fetal parameters and therefore the NOAEL of the test chemical for these parameters were concluded to be 90 mg/kg bw.
Link to relevant study records
- Endpoint:
- developmental toxicity
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Justification for type of information:
- Data is from a study report
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 414 (Prenatal Developmental Toxicity Study)
- Principles of method if other than guideline:
- According to OECD Guideline 414 (Prenatal Developmental Toxicity Study)
- GLP compliance:
- yes
- Limit test:
- no
- Specific details on test material used for the study:
- Name: Ethyltriphenylfosfonium bromide
IUPAC Name: Phosphonium, ethyltriphenyl-, bromide (1:1)
CAS No.: 1530-32-1
Molecular Weight: 371.25 g/mol
Molecular Formula: C20-H20-P.Br
SMILES: [Br-].CC[P+](c1ccccc1)(c2ccccc2)c3ccccc3 - Species:
- rat
- Strain:
- Wistar
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Animals were procured from animal ethics committee approved vendor.
- Age at study initiation: 12-13 weeks
- Weight at study initiation: 228.17 g to 232.55 g
- Fasting period before study: No data available
- Housing: One to three rats were housed in each polycarbonate cage (length 37 cm X breadth 21 cm X height 20 cm). During mating, one male and two female rats were housed in a single cage. Pregnant females were housed individually. Sterilized corn-cob produced from pure corn, dried and free from dust, procured from approved supplier, was used as bedding material. It was renewed as often as necessary to keep the animals dry and clean.
- Diet (e.g. ad libitum): A conventional laboratory pellet diet from approved vendor was offered ad libitum.
- Water (e.g. ad libitum): Aquaguard™ filtered drinking water was offered ad libitum in regularly cleaned bottles.
- Acclimation period: Animals were acclimatised to the test conditions for at least 5 days prior to estrous cycle evaluation.
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 21.0 to 24.5 °C
- Humidity (%): 43.8 to 64.7 %.
- Air changes (per hr): At least 12 changes per hour
- Photoperiod (hrs dark / hrs light): 12 hours light and 12 hours dark.
IN-LIFE DATES:
From: June 5, 2020
To: July 6, 2020 - Route of administration:
- oral: gavage
- Vehicle:
- water
- Remarks:
- Distilled Water
- Details on exposure:
- PREPARATION OF DOSING SOLUTIONS: The vehicle used for dose administration was distilled water. The test chemical was weighed and dissolved in distilled water to achieve the desired concentration of the test chemical at each dose level. Formulations were prepared on the same day or one day prior to dose administration and stored at room temperature until usage as the test chemical stability in solution was proved up to 24 hours.
DIET PREPARATION
- Rate of preparation of diet (frequency): No data available
- Mixing appropriate amounts with (Type of food): No data available
- Storage temperature of food: No data available
VEHICLE
- Justification for use and choice of vehicle (if other than water): Distilled water was used as a vehicle.
- Concentration in vehicle: 0 mg/ml, 1 mg/ml, 3 mg/ml and 9 mg/ml for 0, mg/kg bw/day, 10 mg/kg bw/day, 30 mg/kg bw/day and 90 mg/kg bw/day, respectively
- Amount of vehicle (if gavage): 10 ml/kg
- Lot/batch no. (if required): No data available
- Purity: No data available - Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- Mobile Phase
A - Acetonitrile:
B – Water
Ratio: (A:B = 45:55, v/v)
Column: Zorbax Extend C18 (150 mm x 4.6 mm x 5 µm)
Oven Temperature: 25 °C
Detector: VWD
Wavelength: 210 nm
Flow rate: 1.0 mL/min
Injection Volume: 10 µL
The active ingredient content in dose formulation of test item was determined using a validated analytical method (High Performance Liquid Chromatography – HPLC with VWD). The analytical method was validated in terms of specificity, linearity, precision (% RSD), and accuracy (% Recovery), homogeneity and stability in dose formulation samples using Distilled water as Vehicle. It was confirmed from the results of the validation that the method was specific, linear, precise, accurate, homogeneous and stable for the analysis of the test chemical in dose formulation samples. The results of validation criteria were well within the acceptable limits of the guideline specifications. - Details on mating procedure:
- - Impregnation procedure: cohoused
- If cohoused: Yes
- M/F ratio per cage: For mating, two females were kept with a single male (2:1 pairing)
- Length of cohabitation: Until the evidence of copulation was observed.
- After ... days of unsuccessful pairing replacement of first male by another male with proven fertility: No Data
- Further matings after two unsuccessful attempts: no
- Verification of same strain and source of both sexes: yes
- Proof of pregnancy: sperm in vaginal smear] referred to as day of pregnancy
- Any other deviations from standard protocol: No data available - Duration of treatment / exposure:
- Gestation Day 5 to Gestation 19
- Frequency of treatment:
- Once Daily from GD 5 to 19.
- Duration of test:
- 120-130 days
- Dose / conc.:
- 0 mg/kg bw/day (actual dose received)
- Remarks:
- Control Group
- Dose / conc.:
- 10 mg/kg bw/day (actual dose received)
- Remarks:
- Low Dose Group
- Dose / conc.:
- 30 mg/kg bw/day (actual dose received)
- Remarks:
- Mid Dose Group
- Dose / conc.:
- 90 mg/kg bw/day (actual dose received)
- Remarks:
- High Dose Group
- No. of animals per sex per dose:
- 25 pregnant females per dose
- Control animals:
- yes, concurrent vehicle
- Details on study design:
- - Dose selection rationale: Doses were selected on the basis of previously done dose range finding study wherein the test chemical was administered orally to rats in graduated doses of 20, 60 and 180 mg/kg body weight for 14 consecutive days. Mortality was observed in only one animal of 180 mg/kg body weight group, while no mortalities were observed at 20 or 60 mg/kg body weight dose groups. Body weight was affected for both male and female rats of 180 mg/kg body weight dose group, while no change was observed for animals of mid and low dose groups. Further, test chemical related and dose-dependent lesions in stomach and intestine were observed at all the dose groups, which were also confirmed by histopathological analysis. Based on the above stated results, the doses 0, 10, 30 and 90 mg/kg body weight were selected for control, low, mid and high dose groups of the test chemical in the current study.
- Rationale for animal assignment (if not random): Randomization was done based on body weight of the pregnant females on GD 0.The animals were assigned in an unbiased manner to the control and treatment groups manually. As mating was carried out in batches, females inseminated with same male were evenly distributed across the groups. Individual body weights were within ± 20% of the respective groups mean after randomization.The mean body weights on the day of randomization were analysed by One-way ANOVA and it was found that the group means were statistically comparable to each group.
- Other: No Data Available - Maternal examinations:
- CAGE SIDE OBSERVATIONS: Yes
- Time schedule: All animals were observed twice daily for any morbidity and/or mortality, throughout the acclimatization and study period.
DETAILED CLINICAL OBSERVATIONS: Yes
- Time schedule: All animals were observed daily for clinical signs and symptoms after dose administration. These observations were regularly performed approximately 1 hour after dose administration, since onset of clinical signs after oral gavage is anticipated in that time frame.
BODY WEIGHT: Yes
- Time schedule for examinations: Animals were weighed at the time of receipt, on GD 0, on the first day of dosing (GD 5), and on gestation days 8, 11, 14, 17 and 20.
FOOD CONSUMPTION AND COMPOUND INTAKE (if feeding study): Yes, The weight of feed provided and that leftover was recorded for each cage on the same day as animal body weight. This data was used to calculate mean feed consumption (g/day/rat) on gestation days 5, 8, 11, 14, 17 and 20.
- Food consumption for each animal determined and mean daily diet consumption calculated as g food/kg body weight/day: No data
- Compound intake calculated as time-weighted averages from the consumption and body weight gain data: No data
WATER CONSUMPTION AND COMPOUND INTAKE (if drinking water study): No data
- Time schedule for examinations: No data
POST-MORTEM EXAMINATIONS: Yes
- Sacrifice on gestation day # 20
- Organs examined: The total weight of the gravid or non-gravid uteri including cervix were recorded for all animals. The ovarian and placental weights were determined for all pregnant animals. Also, thyroid and parathyroid examinations were also performed. Also, changes in the visceral organs were also examined.
OTHER: No data available - Ovaries and uterine content:
- The ovaries and uterine content was examined after termination: Yes
Examinations included:
- Gravid uterus weight: Yes
- Number of corpora lutea: Yes
- Number of implantations: Yes
- Number of early resorptions: Yes
- Number of late resorptions: Yes
- Other: Placental weights were determined for all pregnant animals. - Fetal examinations:
- - External examinations: Yes: all per litter
- Soft tissue examinations: Yes: all per litter
- Skeletal examinations: Yes: all per litter
- Head examinations: Yes: half per litter - Statistics:
- Raw data were processed using statistical software “Sigma Plot 14.0”. The mean and standard deviation were calculated using the software and all data were summarized in tabular form. All continuous data (body weight, feed consumption, hormone estimation, absolute and relative organ weights, maternal and pup parameters) were checked for normality using Shapiro Wilk test. All homogenous data was analysed using ANOVA and data showing significance in their variances was subjected to Dunnett’s t-test. All heterogeneous data was analysed using Kruskal-Wallis, ANOVA on ranks. Gross, skeletal and visceral abnormalities were represented as both the total no. of foetuses and litters affected and the percentage of foetuses and litters affected. Further, the data of percent incidences of abnormalities were analysed for dose dependency by Pearson’s correlation. P values of < 0.05 were deemed to be statistically significant.
- Indices:
- Maternal Fertility Index, Pregnancy Index, Gestation Index, Implantation Index, Resorption Index, Litter Index, Fetal Viability Index,
- Historical control data:
- No data available
- Clinical signs:
- no effects observed
- Description (incidence and severity):
- No treatment-related clinical signs or symptoms were observed in any of the animals through the study period.
- Dermal irritation (if dermal study):
- not specified
- Mortality:
- no mortality observed
- Description (incidence):
- No mortality or morbidity was recorded in animals of any of the experimental groups throughout the duration of the experiment.
- Body weight and weight changes:
- no effects observed
- Description (incidence and severity):
- The mean body weight of pregnant and non-pregnant females remained comparable among all the groups for every time point (GD 0, 5, 8, 11, 14, 17 and 20) recorded during the study period. The percent change in body weights with respect to the first day of gestation was also statistically comparable among all the groups of Pregnant and non-pregnant females.
- Food consumption and compound intake (if feeding study):
- no effects observed
- Description (incidence and severity):
- The mean feed consumed per day for pregnant females remained statistically equivalent in all groups of pregnant and non-pregnant females.
- Food efficiency:
- not specified
- Water consumption and compound intake (if drinking water study):
- not specified
- Ophthalmological findings:
- not specified
- Haematological findings:
- not specified
- Clinical biochemistry findings:
- effects observed, treatment-related
- Description (incidence and severity):
- Triiodothryronine (T3) and thyroid stimulating hormone (TSH) levels in sera were found to be statistically comparable among the control and treatment groups in both pregnant and non-pregnant females. However, significant decrease in thyroxine (T4) levels were observed in pregnant females of G4 (90 mg/kg) group as compared to G1 (Control) group (P<0.01).
- Urinalysis findings:
- not specified
- Behaviour (functional findings):
- not specified
- Immunological findings:
- not specified
- Organ weight findings including organ / body weight ratios:
- effects observed, non-treatment-related
- Description (incidence and severity):
- Absolute weights and weights relative to body weight of gravid uterus and ovary remained comparable for pregnant females of control and treatment groups. A statistically significant increase was observed in absolute weight of thyroid-parathyroid in pregnant females of G4 group (90 mg/kg) as compared to G1 (control) group (P<0.05). However, when thyroid-parathyroid weights relative to body weights were compared, no significant difference was observed between control and treatment groups. Absolute and relative weights of uterus, ovary, thyroid and parathyroid of non-pregnant females between control and treatment groups remained comparable. The mean feed consumed per day for pregnant females remained statistically equivalent in all groups of pregnant and non-pregnant females.
- Gross pathological findings:
- no effects observed
- Description (incidence and severity):
- Dams were euthanized and subjected to gross pathology examination. No gross pathological alterations were observed for pregnant and non-pregnant females of control (G1) or treated groups (G2, G3, G4).
- Neuropathological findings:
- not specified
- Histopathological findings: non-neoplastic:
- effects observed, non-treatment-related
- Description (incidence and severity):
- Thyroid glands from G1 (control) and G4 (90 mg/kg body weight) were subjected to microscopic examination. Congenital cyst (ultimobranchial origin) of thyroid gland was found in 3 animals of each G1 (control) and G4 (90 mg/kg body weight) group. Although congenital cysts were observed for thyroid and parathyroid glands of G4 (90 mg/kg body weight) animals, they were concurrently observed in G1 (Control) group. Furthermore, these cysts are spontaneous in nature and not attributable to the test chemical.
- Histopathological findings: neoplastic:
- not specified
- Other effects:
- not specified
- Details on results:
- No treatment-related clinical signs or symptoms were observed in any of the animals through the study period. No mortality or morbidity was recorded in animals of any of the experimental groups throughout the duration of the experiment. The mean body weight of pregnant and non-pregnant females remained comparable among all the groups for every time point (GD 0, 5, 8, 11, 14, 17 and 20) recorded during the study period. The percent change in body weights with respect to the first day of gestation was also statistically comparable among all the groups of Pregnant and non-pregnant females. Triiodothryronine (T3) and thyroid stimulating hormone (TSH) levels in sera were found to be statistically comparable among the control and treatment groups in both pregnant and non-pregnant females. However, significant decrease in thyroxine (T4) levels were observed in pregnant females of G4 (90 mg/kg) group as compared to G1 (Control) group (P<0.01). Absolute weights and weights relative to body weight of gravid uterus and ovary remained comparable for pregnant females of control and treatment groups. A statistically significant increase was observed in absolute weight of thyroid-parathyroid in pregnant females of G4 group (90 mg/kg) as compared to G1 (control) group (P<0.05). However, when thyroid-parathyroid weights relative to body weights were compared, no significant difference was observed between control and treatment groups. Absolute and relative weights of uterus, ovary, thyroid and parathyroid of non-pregnant females between control and treatment groups remained comparable. The mean feed consumed per day for pregnant females remained statistically equivalent in all groups of pregnant and non-pregnant females. Dams were euthanized and subjected to gross pathology examination. No gross pathological alterations were observed for pregnant and non-pregnant females of control (G1) or treated groups (G2, G3, G4). Thyroid glands from G1 (control) and G4 (90 mg/kg body weight) were subjected to microscopic examination. Congenital cyst (ultimobranchial origin) of thyroid gland was found in 3 animals of each G1 (control) and G4 (90 mg/kg body weight) group. Although congenital cysts were observed for thyroid and parathyroid glands of G4 (90 mg/kg body weight) animals, they were concurrently observed in G1 (Control) group. Furthermore, these cysts are spontaneous in nature and not attributable to the test chemical.
- Number of abortions:
- effects observed, non-treatment-related
- Description (incidence and severity):
- At termination 24/25, 24/25, 24/25 and 21/25 females were found to be pregnant from G1 (control), G2 (10 mg/kg body weight), G3 (30 mg/kg body weight) and G4 (90 mg/kg body weight) group respectively. This effect was not considered to be related to the test chemical administration.
- Pre- and post-implantation loss:
- no effects observed
- Description (incidence and severity):
- No test chemical administration related adverse effect on the pre- and post-implantation losses was observed and remained comparable among all the treatment groups and control group.
- Total litter losses by resorption:
- no effects observed
- Description (incidence and severity):
- No significant difference was observed for the mean litter size as there were no significant litter losses by any resorptions across all dose groups.
- Early or late resorptions:
- effects observed, non-treatment-related
- Description (incidence and severity):
- One female from each G1, G2 and G4 had very early resorption which was identified by staining the uterus with ammonium sulphide solution. This effect was no considered as treatment related since it did not have any dose dependent increase and was also observed in the control group.
- Dead fetuses:
- no effects observed
- Description (incidence and severity):
- No dead fetuses were observed across all dose groups due to the test chemical administration.
- Changes in pregnancy duration:
- no effects observed
- Description (incidence and severity):
- No changes in pregnancy duration was observed in all females across all the dose groups due to the test chemical administration.
- Changes in number of pregnant:
- effects observed, non-treatment-related
- Description (incidence and severity):
- At termination 24/25, 24/25, 24/25 and 21/25 females were found to be pregnant from G1 (control), G2 (10 mg/kg body weight), G3 (30 mg/kg body weight) and G4 (90 mg/kg body weight) group respectively. This effect was not considered to be related to the test chemical administration.
- Other effects:
- not specified
- Details on maternal toxic effects:
- No test chemical administration related adverse effect on the pre- and post-implantation losses was observed and remained comparable among all the treatment groups and control group. No significant difference was observed for the mean litter size as there were no significant litter losses by any resorptions across all dose groups. One female from each G1, G2 and G4 had very early resorption which was identified by staining the uterus with ammonium sulphide solution. This effect was no considered as treatment related since it did not have any dose dependent increase and was also observed in the control group. No dead fetuses were observed across all dose groups due to the test chemical administration. No changes in pregnancy duration was observed in all females across all the dose groups due to the test chemical administration. At termination 24/25, 24/25, 24/25 and 21/25 females were found to be pregnant from G1 (control), G2 (10 mg/kg body weight), G3 (30 mg/kg body weight) and G4 (90 mg/kg body weight) group respectively. This effect was not considered to be related to the test chemical administration.
- Dose descriptor:
- LOAEL
- Effect level:
- 90 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Basis for effect level:
- clinical biochemistry
- Remarks on result:
- other: Please see 'remarks'
- Remarks:
- Significant decrease in thyroxine (T4) levels were observed in pregnant females of G4 (90 mg/kg) group as compared to G1 (Control) group. This decrease in T4 level is deemed to be test chemical administration related.
- Key result
- Dose descriptor:
- NOAEL
- Effect level:
- 90 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Basis for effect level:
- body weight and weight gain
- changes in number of pregnant
- changes in pregnancy duration
- clinical signs
- dead fetuses
- early or late resorptions
- effects on pregnancy duration
- food consumption and compound intake
- gross pathology
- histopathology: non-neoplastic
- maternal abnormalities
- mortality
- necropsy findings
- number of abortions
- organ weights and organ / body weight ratios
- pre and post implantation loss
- total litter losses by resorption
- Remarks on result:
- not determinable due to absence of adverse toxic effects
- Key result
- Abnormalities:
- no effects observed
- Fetal body weight changes:
- effects observed, non-treatment-related
- Description (incidence and severity):
- The weights of placenta remained comparable for control (G1) and treatment groups (G2, G3 and G4). The mean weight of male foetuses significantly increased in G2 (10 mg/kg body weight) (P<0.01) as compared to G1 (control). Such change in body weight was not observed in other dose groups and therefore it was considered as an incidental finding.
- Reduction in number of live offspring:
- no effects observed
- Description (incidence and severity):
- There were no dead fetuses and reduction in number of live offsprings across all the dose groups due to test chemical administration.
- Changes in sex ratio:
- no effects observed
- Description (incidence and severity):
- No significant changes in the sex ratio of fetuses were observed across all the dose groups due to test chemical administration.
- Changes in litter size and weights:
- no effects observed
- Description (incidence and severity):
- No significant changes in the litter sizes and weights were observed across all the dose groups due to test chemical administration.
- Changes in postnatal survival:
- not specified
- External malformations:
- effects observed, non-treatment-related
- Description (incidence and severity):
- Gross external observation of foetuses revealed that 5.26, 2.08, 2.76 and 7.11 percentage of foetuses from G1 (control), G2 (10 mg/kg), G3 (30 mg/kg) and G4 (90 mg/kg) respectively showed malformations/variations. The variation included haemorrhage in 0.79 percent of foetuses of G4 (90 mg/kg body weight) group and the malformations included: retarded growth (Runt): 3.86 (G1), 2.08 (G2), 2.76 (G3) and 5.93 (G4) percent of foetuses; dome-shaped head (Meningo-encephalocele): 1.4 (G1) and 1.19 (G4) percent of foetuses. No correlation was observed for the doses of the test chemical and the total percent of foetuses with malformations/variations. Similarly, no significant correlation was observed when litter was used as the unit for comparing the malformations/ variations or when data of individual malformations/variations were compared. These observations were found to be independent of the treatment and rather seem to be spontaneous in nature as observed by other studies
- Skeletal malformations:
- effects observed, non-treatment-related
- Description (incidence and severity):
- Skeletal malformations observed in skull included: hole in skull (mainly in interparietal and occipital region) observed in 5 (1) foetuses (litter) from G1 (Control group) and 3 (1) foetuses (litter) from G4 (90 mg/kg body weight); Bipartite ossification of inter-parietal found in 4 (1) foetuses (litter) from G1 (control) and 3 (1) foetuses (litter) from G4 (90 mg/kg body weight); Bipartite ossification and incomplete ossification of occipital found in 1 foetus from G1 (control) and G4 (90 mg/kg body weight) respectively. Although the number of foetuses with malformations of skull seems to be high, these observations were only present in foetuses of 1 litter each from G1 and G4 group. One rib was absent in 1 foetus from G3 (30 mg/kg body weight) and the same foetus had branched rib; 2 (2), 4 (3), 2 (2) and 2 (1) foetuses (litters) from G1, G2, G3 and G4 respectively showed misaligned ribs. Unossified/incompletely ossified sternebrae were observed in 3 (1), and 2 (1) foetuses (litters) of G1 and G3 respectively; misaligned sternebrae were seen in 1 foetus of G2. Fused cervical vertebrae were observed in 1 foetus of G1. The total percentage of foetuses with skeletal malformations/variations were 6.80, 2.65, 3.36 and 3.76 for G1 (control), G2 (10 mg/kg), G3 (30 mg/kg) and G4 (90 mg/kg) respectively while the percentage of litters affected were found to be 17.39 (G1), 13.04 (G2), 16.67 (G3) and 10.00 (G4). No significant correlation was observed between treatment and individual skeletal malformations/variations or total percentages of foetuses and litters affected. The skeletal malformations/variations noted in treatment group were concurrently seen in control group. Moreover, the occurrence and incidences of these malformations/variations are common in developing foetuses. Therefore, these skeletal developmental malformations/variations were not considered to be test chemical related.
- Visceral malformations:
- effects observed, non-treatment-related
- Description (incidence and severity):
- In visceral observations, hematoma (ankle of left hind limb) was found in 1 foetus from G2 (10 mg/kg body weight) and enlarged adrenal with reduced thymus size was found in 1 foetus from G3 (30 mg/kg body weight) group. No malformations/variations were observed in any other foetuses of control or treated groups. Head razor examination of foetuses did not show any malformations/variations in control or treated groups.
- Other effects:
- no effects observed
- Description (incidence and severity):
- No significant effects were observed for the AGD and normalised AGD among all the groups. Similarly, the crown to rump length (CRL) of foetuses were comparable for control (G1) and treatment groups (G2, G3, G4)
- Details on embryotoxic / teratogenic effects:
- The weights of placenta remained comparable for control (G1) and treatment groups (G2, G3 and G4). The mean weight of male foetuses significantly increased in G2 (10 mg/kg body weight) (P<0.01) as compared to G1 (control). Such change in body weight was not observed in other dose groups and therefore it was considered as an incidental finding. There were no dead fetuses and reduction in number of live offsprings across all the dose groups due to test chemical administration. No significant changes in the sex ratio of fetuses were observed across all the dose groups due to test chemical administration. No significant changes in the litter sizes and weights were observed across all the dose groups due to test chemical administration. Gross external observation of foetuses revealed that 5.26, 2.08, 2.76 and 7.11 percentage of foetuses from G1 (control), G2 (10 mg/kg), G3 (30 mg/kg) and G4 (90 mg/kg) respectively showed malformations/variations. The variation included haemorrhage in 0.79 percent of foetuses of G4 (90 mg/kg body weight) group and the malformations included: retarded growth (Runt): 3.86 (G1), 2.08 (G2), 2.76 (G3) and 5.93 (G4) percent of foetuses; dome-shaped head (Meningo-encephalocele): 1.4 (G1) and 1.19 (G4) percent of foetuses. No correlation was observed for the doses of the test chemical and the total percent of foetuses with malformations/variations. Similarly, no significant correlation was observed when litter was used as the unit for comparing the malformations/ variations or when data of individual malformations/variations were compared. These observations were found to be independent of the treatment and rather seem to be spontaneous in nature as observed by other studies. Skeletal malformations observed in skull included: hole in skull (mainly in interparietal and occipital region) observed in 5 (1) foetuses (litter) from G1 (Control group) and 3 (1) foetuses (litter) from G4 (90 mg/kg body weight); Bipartite ossification of inter-parietal found in 4 (1) foetuses (litter) from G1 (control) and 3 (1) foetuses (litter) from G4 (90 mg/kg body weight); Bipartite ossification and incomplete ossification of occipital found in 1 foetus from G1 (control) and G4 (90 mg/kg body weight) respectively. Although the number of foetuses with malformations of skull seems to be high, these observations were only present in foetuses of 1 litter each from G1 and G4 group. One rib was absent in 1 foetus from G3 (30 mg/kg body weight) and the same foetus had branched rib; 2 (2), 4 (3), 2 (2) and 2 (1) foetuses (litters) from G1, G2, G3 and G4 respectively showed misaligned ribs. Unossified/incompletely ossified sternebrae were observed in 3 (1), and 2 (1) foetuses (litters) of G1 and G3 respectively; misaligned sternebrae were seen in 1 foetus of G2. Fused cervical vertebrae were observed in 1 foetus of G1. The total percentage of foetuses with skeletal malformations/variations were 6.80, 2.65, 3.36 and 3.76 for G1 (control), G2 (10 mg/kg), G3 (30 mg/kg) and G4 (90 mg/kg) respectively while the percentage of litters affected were found to be 17.39 (G1), 13.04 (G2), 16.67 (G3) and 10.00 (G4). No significant correlation was observed between treatment and individual skeletal malformations/variations or total percentages of foetuses and litters affected. The skeletal malformations/variations noted in treatment group were concurrently seen in control group. Moreover, the occurrence and incidences of these malformations/variations are common in developing foetuses. Therefore, these skeletal developmental malformations/variations were not considered to be test chemical related. In visceral observations, hematoma (ankle of left hind limb) was found in 1 foetus from G2 (10 mg/kg body weight) and enlarged adrenal with reduced thymus size was found in 1 foetus from G3 (30 mg/kg body weight) group. No malformations/variations were observed in any other foetuses of control or treated groups. Head razor examination of foetuses did not show any malformations/variations in control or treated groups.
- Key result
- Dose descriptor:
- NOAEL
- Effect level:
- 90 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- reduction in number of live offspring
- changes in sex ratio
- fetal/pup body weight changes
- changes in litter size and weights
- external malformations
- skeletal malformations
- visceral malformations
- Remarks on result:
- not determinable due to absence of adverse toxic effects
- Key result
- Abnormalities:
- no effects observed
- Key result
- Developmental effects observed:
- no
- Treatment related:
- no
- Conclusions:
- Based on all the available data, it was concluded that there were no test chemical related adverse effects that were observed on the maternal reproductive/developmental toxicity and also fetal parameters. Although, significant decrease in T4 levels in thyroid estimations indicate towards maternal systemic toxicity. Therefore, the LOAEL for maternal systemic toxicity was observed to be 30 mg/kg bw/day, while the NOAEL for the maternal reproductive/developmental toxicity and fetal developmental toxicity was observed to be 90 mg/kg bw/day.
- Executive summary:
A study according to Prenatal Developmental Toxicity Study, adopted: 25thJune 2018 was performed using a total of 100 pregnant female Wistar rats. The test chemical was administered to these pregnant female Wistar rats by oral: gavage route and the vehicle used to dissolve the test chemical was distilled water. The test chemical was soluble in distilled water in the in-house solubility test and therefore, distilled water was chosen as the vehicle. The 100 pregnant females were randomized into 4 experimental groups containing 25 animals each. The groups, viz., G1, G2, G3 and G4 received 0, 10, 30 and 90 mg/kg bw/day of the test chemical, respectively. The test chemical was administered to these pregnant rats during Gestation Day 5 to 19 at the frequency of once daily. The doses were selected on the basis of previously done, dose range finding study (DRF study). In this study, the test chemical was administered orally to rats in graduated doses of 20, 60 and 180 mg/kg body weight for 14 consecutive days. Mortality was observed in only one animal of 180 mg/kg body weight group, while no mortalities were observed at 20 or 60 mg/kg body weight dose groups. Body weight was affected for both male and female rats of 180 mg/kg body weight dose group, while no change was observed for animals of mid and low dose groups. Further, test chemical related and dose-dependent lesions in stomach and intestine were observed at all the dose groups, which were also confirmed by histopathological analysis. Based on the above stated results, the doses 0, 10, 30 and 90 mg/kg body weight were selected for control, low, mid and high dose groups, respectively in the main study. In this study, all the animals were observed twice daily for any morbidity and/or mortality, throughout the acclimatization and study period. All animals were observed daily for clinical signs and symptoms after dose administration. These observations were regularly performed approximately 1 hour after dose administration, since onset of clinical signs after oral gavage is anticipated in that time frame. Animals were weighed at the time of receipt, on GD 0, on the first day of dosing (GD 5), and on gestation days 8, 11, 14, 17 and 20. The weight of feed provided and that leftover was recorded for each cage on the same day as animal body weight. This data was used to calculate mean feed consumption (g/day/rat) on gestation days 5, 8, 11, 14, 17 and 20. From all dams at termination, blood was collected in the morning; serum was separated and stored under appropriate conditions. All collected blood samples were assessed for serum levels of thyroid hormones (T3 and T4) and thyroid stimulating hormone (TSH) using commercially available Rat ELISA kits. All pregnant females were weighed and euthanized on GD 20 (one day prior to expected day of delivery) by using CO2 asphyxiation. Fetuses were euthanized humanely as per the internal SOP. All animals were subjected to complete gross necropsy. From all dams at termination, thyroid gland were collected, weighed (after fixation) and preserved for histopathological examination. Immediately after the termination, uteri were removed, and the pregnancy status of the animals was evaluated. Uteri that appear non-gravid were further examined using ammonium sulphide staining to confirm non-pregnant status. The total weight of the gravid or non-gravid uteri including cervix were recorded for all animals. Further, the number of corpora lutea and the ovarian and placental weights were determined for all pregnant animals. The uterine contents were also examined for the number of implantation sites, number of live/viable fetuses, number of dead fetuses and number of resorptions. Using the above information, pre-implantation and post-implantation loss was calculated as follows: pre-implantations loss = [(no. of corpora lutea – no. of implantations)/ no. of corpora lutea] x 100 and post-implantation loss = [(no. of implantations – no. of viable fetuses/ no. of implantations] x 100. All fetuses were weighed, sexed and examined for external abnormalities and crown to rump length. For live fetuses, anogenital distances (AGD) were measured. The fetuses were examined for skeletal and soft tissue abnormalities with special emphasis to reproductive organs. Also, male fetuses were evaluated for incomplete testicular descent/cryptorchidism. The one half of each litter were prepared and examined for skeletal abnormalities (growth retardation, delayed ossification, etc.) using Alcian blue and Alizarin red double staining technique and the remainder were prepared for and examined for soft tissue alterations (visceral and head razor sectioning). During observations, no treatment-related clinical signs or symptoms were observed in any of the animals through the study period. No mortality or morbidity was recorded in animals of any of the experimental groups throughout the duration of the experiment. The mean body weight of pregnant and non-pregnant females remained comparable among all the groups for every time point (GD 0, 5, 8, 11, 14, 17 and 20) recorded during the study period. The percent change in body weights with respect to the first day of gestation was also statistically comparable among all the groups of Pregnant and non-pregnant females. Triiodothryronine (T3) and thyroid stimulating hormone (TSH) levels in sera were found to be statistically comparable among the control and treatment groups in both pregnant and non-pregnant females. However, significant decrease in thyroxine (T4) levels were observed in pregnant females of G4 (90 mg/kg) group as compared to G1 (Control) group (P<0.01). Absolute weights and weights relative to body weight of gravid uterus and ovary remained comparable for pregnant females of control and treatment groups. A statistically significant increase was observed in absolute weight of thyroid-parathyroid in pregnant females of G4 group (90 mg/kg) as compared to G1 (control) group (P<0.05). However, when thyroid-parathyroid weights relative to body weights were compared, no significant difference was observed between control and treatment groups. Absolute and relative weights of uterus, ovary, thyroid and parathyroid of non-pregnant females between control and treatment groups remained comparable. The mean feed consumed per day for pregnant females remained statistically equivalent in all groups of pregnant and non-pregnant females. Dams were euthanized and subjected to gross pathology examination. No gross pathological alterations were observed for pregnant and non-pregnant females of control (G1) or treated groups (G2, G3, G4). Thyroid glands from G1 (control) and G4 (90 mg/kg body weight) were subjected to microscopic examination. Congenital cyst (ultimo branchial origin) of thyroid gland was found in 3 animals of each G1 (control) and G4 (90 mg/kg body weight) group. Although congenital cysts were observed for thyroid and parathyroid glands of G4 (90 mg/kg body weight) animals, they were concurrently observed in G1 (Control) group. Furthermore, these cysts are spontaneous in nature and not attributable to the test chemical. No test chemical administration related adverse effect on the pre- and post-implantation losses was observed and remained comparable among all the treatment groups and control group. No significant difference was observed for the mean litter size as there were no significant litter losses by any resorptions across all dose groups. One female from each G1, G2 and G4 had very early resorption which was identified by staining the uterus with ammonium sulphide solution. This effect was no considered as treatment related since it did not have any dose dependent increase and was also observed in the control group. No dead fetuses were observed across all dose groups due to the test chemical administration. No changes in pregnancy duration was observed in all females across all the dose groups due to the test chemical administration. At termination 24/25, 24/25, 24/25 and 21/25 females were found to be pregnant from G1 (control), G2 (10 mg/kg body weight), G3 (30 mg/kg body weight) and G4 (90 mg/kg body weight) group respectively. This effect was not considered to be related to the test chemical administration. The weights of placenta remained comparable for control (G1) and treatment groups (G2, G3 and G4). The mean weight of male foetuses significantly increased in G2 (10 mg/kg body weight) (P<0.01) as compared to G1 (control). Such change in body weight was not observed in other dose groups and therefore it was considered as an incidental finding. There were no dead fetuses and reduction in number of live off springs across all the dose groups due to test chemical administration. No significant changes in the sex ratio of fetuses were observed across all the dose groups due to test chemical administration. No significant changes in the litter sizes and weights were observed across all the dose groups due to test chemical administration. Gross external observation of foetuses revealed that 5.26, 2.08, 2.76 and 7.11 percentage of foetuses from G1 (control), G2 (10 mg/kg), G3 (30 mg/kg) and G4 (90 mg/kg) respectively showed malformations/variations. The variation included haemorrhage in 0.79 percent of foetuses of G4 (90 mg/kg body weight) group and the malformations included: retarded growth (Runt): 3.86 (G1), 2.08 (G2), 2.76 (G3) and 5.93 (G4) percent of fetuses; dome-shaped head (Meningo-encephalocele): 1.4 (G1) and 1.19 (G4) percent of fetuses. No correlation was observed for the doses of the test chemical and the total percent of fetuses with malformations/variations. Similarly, no significant correlation was observed when litter was used as the unit for comparing the malformations/ variations or when data of individual malformations/variations were compared. These observations were found to be independent of the treatment and rather seem to be spontaneous in nature as observed by other studies. Skeletal malformations observed in skull included: hole in skull (mainly in interparietal and occipital region) observed in 5 (1) fetuses (litter) from G1 (Control group) and 3 (1) fetuses (litter) from G4 (90 mg/kg body weight); Bipartite ossification of inter-parietal found in 4 (1) fetuses (litter) from G1 (control) and 3 (1) fetuses (litter) from G4 (90 mg/kg body weight); Bipartite ossification and incomplete ossification of occipital found in 1 fetus from G1 (control) and G4 (90 mg/kg body weight) respectively. Although the number of fetuses with malformations of skull seems to be high, these observations were only present in fetuses of 1 litter each from G1 and G4 group. One rib was absent in 1 fetus from G3 (30 mg/kg body weight) and the same fetus had branched rib; 2 (2), 4 (3), 2 (2) and 2 (1) fetuses (litters) from G1, G2, G3 and G4 respectively showed misaligned ribs. Unossified/incompletely ossified sternebrae were observed in 3 (1), and 2 (1) fetuses (litters) of G1 and G3 respectively; misaligned sternebrae were seen in 1 fetus of G2. Fused cervical vertebrae were observed in 1 fetus of G1. The total percentage of fetuses with skeletal malformations/variations were 6.80, 2.65, 3.36 and 3.76 for G1 (control), G2 (10 mg/kg), G3 (30 mg/kg) and G4 (90 mg/kg) respectively while the percentage of litters affected were found to be 17.39 (G1), 13.04 (G2), 16.67 (G3) and 10.00 (G4). No significant correlation was observed between treatment and individual skeletal malformations/variations or total percentages of fetuses and litters affected. The skeletal malformations/variations noted in treatment group were concurrently seen in control group. Moreover, the occurrence and incidences of these malformations/variations are common in developing fetuses. Therefore, these skeletal developmental malformations/variations were not considered to be test chemical related. In visceral observations, hematoma (ankle of left hind limb) was found in 1 fetus from G2 (10 mg/kg body weight) and enlarged adrenal with reduced thymus size was found in 1 fetus from G3 (30 mg/kg body weight) group. No malformations/variations were observed in any other fetuses of control or treated groups. Head razor examination of fetuses did not show any malformations/variations in control or treated groups. Based on all the available data, it was concluded that there were no test chemical related adverse effects that were observed on the maternal reproductive/developmental toxicity and also fetal parameters. Although, significant decrease in T4 levels in thyroid estimations indicate towards maternal systemic toxicity. Therefore, the LOAEL for maternal systemic toxicity was observed to be 30 mg/kg bw/day, while the NOAEL for the maternal reproductive/developmental toxicity and fetal developmental toxicity was observed to be 90 mg/kg bw/day.
Reference
Table for Mortality and Morbidity
Group | Dose (mg/kg) | No. of Animals | Gestation Day | Observation | |
Morning | Evening | ||||
G1 | 0 | 25 | 0-20 | No mortality/ morbidity | No mortality/ morbidity |
G2 | 10 | 25 | 0-20 | No mortality/ morbidity | No mortality/ morbidity |
G3 | 30 | 25 | 0-20 | No mortality/ morbidity | No mortality/ morbidity |
G4 | 90 | 25 | 0-20 | No mortality/ morbidity | No mortality/ morbidity |
Table for General Clinical Signs Observation
Group | Dose (mg/kg) | No. Of Animals | Animal Number | Gestation Day | Clinical Signs |
G1 | 0 | 25 | 1-25 | 0-20 | Normal |
G2 | 10 | 25 | 26-50 | 0-20 | Normal |
G3 | 30 | 25 | 51-75 | 0-20 | Normal |
G4 | 90 | 25 | 76-100 | 0-20 | Normal |
Table for Body Weight
Pregnant Females | |||||||||
Group | Dose (mg/kg) |
| Day of gestation and body weight in grams | ||||||
0 | 5 | 8 | 11 | 14 | 17 | 20 | |||
G1 | 0 | Mean | 228.17 | 250.57 | 260.83 | 274.70 | 290.26 | 318.48 | 355.43 |
SD | 14.31 | 14.59 | 15.97 | 17.15 | 19.11 | 18.02 | 23.23 | ||
N | 23 | 23 | 23 | 23 | 23 | 23 | 23 | ||
G2 | 10 | Mean | 230.26 | 254.22 | 264.09 | 278.22 | 294.39 | 320.57 | 358.96 |
SD | 14.08 | 15.03 | 16.09 | 16.21 | 18.10 | 20.63 | 24.42 | ||
N | 23 | 23 | 23 | 23 | 23 | 23 | 23 | ||
G3 | 30 | Mean | 231.04 | 253.33 | 263.38 | 277.83 | 293.33 | 318.71 | 357.42 |
SD | 12.61 | 12.74 | 14.56 | 15.62 | 15.56 | 16.06 | 17.55 | ||
N | 24 | 24 | 24 | 24 | 24 | 24 | 24 | ||
G4 | 90 | Mean | 232.55 | 254.75 | 262.85 | 278.00 | 293.15 | 318.15 | 358.00 |
SD | 14.52 | 17.01 | 17.92 | 19.43 | 20.58 | 22.12 | 26.77 | ||
N | 20 | 20 | 20 | 20 | 20 | 20 | 20 |
Non-Pregnant Female | |||||||||
Group | Dose (mg/kg) | Day of gestation and body weight in grams | |||||||
0 | 5 | 8 | 11 | 14 | 17 | 20 | |||
G1 | 0 | Mean | 230.50 | 252.50 | 255.50 | 270.00 | 260.00 | 251.50 | 259.00 |
SD | 33.23 | 33.23 | 34.65 | 33.94 | 33.94 | 31.82 | 32.53 | ||
N | 2 | 2 | 2 | 2 | 2 | 2 | 2 | ||
G2 | 10 | Mean | 217.50 | 227.00 | 217.50 | 205.00 | 215.50 | 217.50 | 222.00 |
SD | 9.19 | 19.8 | 6.36 | 28.28 | 9.19 | 12.02 | 4.24 | ||
N | 2 | 2 | 2 | 2 | 2 | 2 | 2 | ||
G3 | 30 | Mean | 235.00 | 255.00 | 263.00 | 272.00 | 263.00 | 259.00 | 268.00 |
SD | ./. | ./. | ./. | ./. | ./. | ./. | ./. | ||
N | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||
G4 | 90 | Mean | 232.20 | 258.20 | 265.20 | 274.80 | 266.60 | 262.60 | 263.40 |
SD | 9.73 | 13.65 | 16.48 | 14.52 | 17.43 | 15.42 | 14.45 | ||
N | 5 | 5 | 5 | 5 | 5 | 5 | 5 |
Key: SD: Standard deviation; N: No. of animals; ./.: Not applicable
Table for Body weight Change:
Pregnant Females | ||||||||
Group | Dose (mg/kg) | Gestation Day and body weight change (%) | ||||||
5 | 8 | 11 | 14 | 17 | 20 | |||
G1 | 0 | Mean | 9.86 | 14.35 | 20.44 | 27.25 | 39.68 | 55.84 |
SD | 2.27 | 2.83 | 3.80 | 4.21 | 3.93 | 5.76 | ||
N | 23 | 23 | 23 | 23 | 23 | 23 | ||
G2 | 10 | Mean | 10.44 | 14.73 | 20.91 | 27.91 | 39.29 | 55.99 |
SD | 2.32 | 3.02 | 3.84 | 3.83 | 5.13 | 7.25 | ||
N | 23 | 23 | 23 | 23 | 23 | 23 | ||
G3 | 30 | Mean | 9.69 | 14.03 | 20.28 | 27.03 | 38.04 | 54.87 |
SD | 1.96 | 2.87 | 3.13 | 3.93 | 4.31 | 6.39 | ||
N | 24 | 24 | 24 | 24 | 24 | 24 | ||
G4 | 90 | Mean | 9.56 | 13.04 | 19.58 | 26.09 | 36.90 | 54.08 |
SD | 2.99 | 3.44 | 4.90 | 5.18 | 6.83 | 9.57 | ||
N | 20 | 20 | 20 | 20 | 20 | 20 |
Non-Pregnant Females | ||||||||
Group | Dose (mg/kg) |
| Gestation Day and body weight change (%) | |||||
5 | 8 | 11 | 14 | 17 | 20 | |||
G1 | 0 | Mean | 9.65 | 10.92 | 17.30 | 12.91 | 9.25 | 12.52 |
SD | 1.39 | 0.95 | 2.18 | 1.56 | 1.95 | 2.11 | ||
N | 2 | 2 | 2 | 2 | 2 | 2 | ||
G2 | 10 | Mean | 4.27 | 0.15 | -5.39 | -0.75 | 0.21 | 2.21 |
SD | 4.7 | 7.16 | 17.01 | 8.42 | 9.77 | 6.27 | ||
N | 2 | 2 | 2 | 2 | 2 | 2 | ||
G3 | 30 | Mean | 8.51 | 11.91 | 15.74 | 11.91 | 10.21 | 14.04 |
SD | ./. | ./. | ./. | ./. | ./. | ./. | ||
N | 1 | 1 | 1 | 1 | 1 | 1 | ||
G4 | 90 | Mean | 11.19 | 14.19 | 18.33 | 14.87 | 13.15 | 13.46 |
SD | 3.06 | 4.25 | 2.69 | 7.05 | 6.16 | 4.59 | ||
N | 5 | 5 | 5 | 5 | 5 | 5 |
Key: SD: Standard deviation; N: No. of animals; ./.: Not applicable
Table for Maternal Evaluation
Groups | G1 | G2 | G3 | G4 |
Dose (mg/kg body weight) | 0 | 10 | 30 | 90 |
Initial animals per group | 25 | 25 | 25 | 25 |
Confirmed Pregnancy at necropsy | 24 | 24 | 24 | 21 |
Litters with live foetuses | 23 | 23 | 24 | 20 |
Litters with early resorptions | 1 | 1 | 0 | 1 |
Pregnancy rate (%) | 92 | 92 | 96 | 80 |
No. of Corpora lutea | 13.43 ± 1.41 | 13.65 ± 1.61 | 13.67 ±1.40 | 13.60 ± 2.09 |
No. of implantation sites | 12.87 ± 1.74 | 13.22 ± 1.70 | 12.71 ± 1.65 | 13.35 ± 1.84 |
No. of resorptions | 0.48 ± 0.67 | 0.61 ± 0.84 | 0.63 ± 0.82 | 0.70 ± 1.13 |
Pre-implantation loss (%) | 4.30 ± 7.27 | 3.07 ± 6.96 | 6.78 ± 9.84 | 1.55 ± 4.06 |
Post-implantation loss (%) | 3.63 ± 5.05 | 4.58 ± 5.74 | 4.94 ± 6.38 | 5.20 ± 7.84 |
Litter size | 12.39 ± 1.73 | 12.57 ± 1.44 | 12.13 ± 1.75 | 12.65 ± 1.95 |
No. of live foetuses | 12.39 ± 1.73 | 12.57 ± 1.44 | 12.08 ± 1.79 | 12.65 ± 1.95 |
No. of dead foetuses | 0.00 ± 0.00 | 0.00 ± 0.00 | 0.04 ± 0.20 | 0.00 ± 0.00 |
Live Foetuses (%) | 100.00 ± 0.00 | 100.00 ± 0.00 | 99.62 ± 1.86 | 100.00 ± 0.00 |
Values are represented as Mean ± SD.
Pregnancy rate(%) = (No. of females with live foetuses/ No. of mated females) x 100;
Pre-implantations loss = [(no. of corpora lutea − no. of implantations)/ no. of corpora lutea] x 100;
Post-implantation loss = [(no. of implantations - no. of live foetuses)/ no. of total implantations] x 100
Table for Hormone levels (T3, T4 & TSH)
Pregnant Females | |||||
Group | Dose (mg/kg) |
| T3 (ng/mL) | T4 (ng/mL) | TSH (µIU/mL) |
G1 | 0 | Mean | 0.37 | 56.89 | 0.44 |
SD | 0.11 | 9.19 | 0.12 | ||
N | 23 | 23 | 23 | ||
G2 | 10 | Mean | 0.35 | 57.45 | 0.43 |
SD | 0.12 | 8.54 | 0.15 | ||
N | 23 | 23 | 23 | ||
G3 | 30 | Mean | 0.34 | 51.03 | 0.43 |
SD | 0.11 | 10.37 | 0.13 | ||
N | 24 | 24 | 24 | ||
G4 | 90 | Mean | 0.37 | 48.35 ↓↓ | 0.41 |
SD | 0.09 | 10.24 | 0.10 | ||
N | 20 | 20 | 20 |
Non- Pregnant Females | |||||
Group | Dose (mg/kg) |
| T3 (ng/mL) | T4 (ng/mL) | TSH (µIU/mL) |
G1 | 0 | Mean | 0.26 | 48.34 | 0.44 |
SD | 0.04 | 2.35 | 0.12 | ||
N | 2 | 2 | 2 | ||
G2 | 10 | Mean | 0.22 | 37.50 | 0.37 |
SD | 0.06 | 1.17 | 0.16 | ||
N | 2 | 2 | 2 | ||
G3 | 30 | Mean | 0.25 | 56.67 | 0.31 |
SD | ./. | ./. | ./. | ||
N | 1 | 1 | 1 | ||
G4 | 90 | Mean | 0.33 | 34.00 | 0.54 |
SD | 0.07 | 5.35 | 0.11 | ||
N | 5 | 5 | 5 |
Key: SD: Standard deviation; N: No. of animals; ↓↓:Decreased as compared to control (P<0.01)
Table for External Gross Evaluation of Foetuses
Group | G1 | G2 | G3 | G4 |
Dose level (mg/kg body weight) | 0 | 10 | 30 | 90 |
Total No. of Litters with live foetuses | 23 | 23 | 24 | 20 |
Total No. of live Foetuses | 285 | 283 | 290 | 253 |
Total No. of Male Foetuses | 136 | 151 | 137 | 109 |
Total No. of Female Foetuses | 149 | 138 | 153 | 144 |
Weight of foetuses (g) | 3.46 ± 0.44 | 3.53 ± 0.33 | 3.54 ± 0.51 | 3.42 ± 0.33 |
Weight of male foetuses (g) | 3.57 ± 0.46 | 3.65 ± 0.32 ↑↑ | 3.64 ± 0.57 | 3.56 ± 0.30 |
Weight of female foetuses (g) | 3.37 ± 0.38 | 3.41 ± 0.28 | 3.45 ± 0.45 | 3.32 ± 0.30 |
Weight of Placenta (g) | 0.46 ± 0.06 | 0.46 ± 0.06 | 0.47 ± 0.08 | 0.45 ± 0.06 |
Crown to rump length (cm) | 3.45 ± 0.22 | 3.51 ± 0.16 | 3.51 ± 0.20 | 3.46 ± 0.27 |
AGD of Male foetuses (mm) | 2.32 ± 0.17 | 2.35 ± 0.17 | 2.33 ± 0.08 | 2.31 ± 0.08 |
AGD of Female foetuses (mm) | 1.16 ± 0.11 | 1.16 ± 0.10 | 1.15 ± 0.05 | 1.15 ± 0.06 |
Normalised AGD of Male foetuses | 1.52 ± 0.13 | 1.53 ± 0.11 | 1.52 ± 0.08 | 1.52 ± 0.06 |
Normalised AGD of Female foetuses | 0.77 ± 0.08 | 0.77 ± 0.07 | 0.76 ± 0.04 | 0.77 ± 0.04 |
Male/Female sex ratio (per dam) | 1.20 ± 0.97 | 1.37 ± 0.96 | 1.03 ± 0.54 | 0.88 ± 0.51 |
External observations | ||||
Total no. of Foetuses with No Abnormality Detected | 270 | 283 | 282 | 235 |
Total no. of Foetuses with abnormalities | 15 | 6 | 8 | 18 |
Foetuses with abnormalities (%) | 5.26 | 2.08 | 2.76 | 7.11 |
Total no. of Litters with No Abnormality Detected | 12 | 17 | 17 | 9 |
Total no. of Litters with abnormalities | 11 | 6 | 7 | 11 |
Litters with abnormalities (%) | 47.83 | 26.09 | 29.17 | 50.00 |
Abnormalities | ||||
Haemorrhage (V) | 0(0) | 0(0) | 0(0) | 2(2) |
Haemorrhage (%) | 0(0) | 0(0) | 0(0) | 0.79(10) |
Runt (M) | 11(11) | 6(6) | 8(7) | 15(10) |
Runt (%) | 5.26(47.83) | 2.08(26.09) | 2.76(29.17) | 5.93(50.00) |
Dome-shaped Head (M) | 4(1) | 0(0) | 0(0) | 3(1) |
Dome-shaped Head (%) | 1.4(4.35) | 0(0) | 0(0) | 1.19(5.00) |
Values are represented as Mean ± SD; AGD: Anogenital distance; Normalised AGD: AGD/ Body weight (1/3); the incidence of the individual defect is presented as a number/ Percent of foetuses (number/ percent of litters); Abnormalities: includes malformations and variations; M: Malformations; V: Variations; ↑↑:Increased as compared to control (P<0.01).
Table for Skeletal Anomalies of the Foetuses
Groups | G1 | G2 | G3 | G4 | ||||
Dose (mg/kg body weight) | 0 | 10 | 30 | 90 | ||||
| No. | % | No. | % | No. | % | No. | % |
Foetuses examined | 147 | 151 | 149 | 133 | ||||
No abnormality detected | 137 | 93.20 | 147 | 97.35 | 144 | 96.64 | 128 | 96.24 |
Total and % Foetuses with abnormalities | 10 | 6.80 | 4 | 2.65 | 5 | 3.36 | 5 | 3.76 |
Skull | ||||||||
Hole in Skull | 5 | 3.40 | 0 | 0.00 | 0 | 0.00 | 3 | 2.26 |
Bipartite Ossification of interparietal | 4 | 2.72 | 0 | 0.00 | 0 | 0.00 | 3 | 2.26 |
Bipartite Ossification of Occippital | 1 | 0.68 | 0 | 0.00 | 0 | 0.00 | 1 | 0.75 |
Incomplete Ossification of Occipital | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 1 | 0.75 |
Ribs | ||||||||
Rib Misaligned | 2 | 1.36 | 4 | 2.65 | 2 | 1.34 | 2 | 1.50 |
Rib Absent | 0 | 0.00 | 0 | 0.00 | 1 | 0.67 | 0 | 0.00 |
Rib Branched | 0 | 0.00 | 0 | 0.00 | 1 | 0.67 | 0 | 0.00 |
Sternebrae | ||||||||
Sternebra Unossified | 3 | 2.04 | 0 | 0.00 | 2 | 1.34 | 0 | 0.00 |
Sternebra Misaligned | 0 | 0.00 | 1 | 0.66 | 0 | 0.00 | 0 | 0.00 |
Vertebrae | ||||||||
Fused Cervical Vertebrae | 1 | 0.68 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 |
The incidence of the individual defects presented as a number and percentages of foetuses; Abnormalities: includes malformations and variations; M: Malformations; V: Variations
Table for Skeletal Anomalies of the Foetuses (with respect to Litters) (continued)
Groups | G1 | G2 | G3 | G4 | ||||
Dose (mg/kg body weight) | 0 | 10 | 30 | 90 | ||||
| No. | % | No. | % | No. | % | No. | % |
Litters examined | 23 | 23 | 24 | 20 | ||||
No abnormality detected | 19 | 82.61 | 20 | 86.96 | 20 | 83.33 | 18 | 90.00 |
Total and % Litters with abnormalities | 4 | 17.39 | 3 | 13.04 | 4 | 16.67 | 2 | 10.00 |
Skull | ||||||||
Hole in Skull | 1 | 4.35 | 0 | 0.00 | 0 | 0.00 | 1 | 5.00 |
Bipartite Ossification of interparietal | 1 | 4.35 | 0 | 0.00 | 0 | 0.00 | 1 | 5.00 |
Bipartite Ossification of Occippital | 1 | 4.35 | 0 | 0.00 | 0 | 0.00 | 1 | 5.00 |
Incomplete Ossification of Occipital | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 1 | 5.00 |
Ribs | ||||||||
Misaligned | 2 | 8.70 | 3 | 13.04 | 2 | 8.33 | 1 | 5.00 |
Absent | 0 | 0.00 | 0 | 0.00 | 1 | 4.17 | 0 | 0.00 |
Branched | 0 | 0.00 | 0 | 0.00 | 1 | 4.17 | 0 | 0.00 |
Sternebrae | ||||||||
Unossified | 1 | 4.35 | 0 | 0.00 | 1 | 4.17 | 0 | 0.00 |
Misaligned | 0 | 0.00 | 1 | 4.35 | 0 | 0.00 | 0 | 0.00 |
Vertebrae | ||||||||
Fused Cervical Vertebra | 1 | 4.35 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 |
The incidence of the individual defect is presented as a number and percentages of litters
Abnormalities: includes malformations and variations; M: Malformations; V: Variations
Effect on developmental toxicity: via oral route
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- NOAEL
- 90 mg/kg bw/day
- Study duration:
- subacute
- Species:
- rat
- Quality of whole database:
- Data is Klimicsh 1 and from study report
Effect on developmental toxicity: via inhalation route
- Endpoint conclusion:
- no study available
Effect on developmental toxicity: via dermal route
- Endpoint conclusion:
- no study available
Additional information
Developmental toxicity study:
A study according to Prenatal Developmental Toxicity Study, adopted: 25thJune 2018 was performed using a total of 100 pregnant female Wistar rats. The test chemical was administered to these pregnant female Wistar rats by oral: gavage route and the vehicle used to dissolve the test chemical was distilled water. The test chemical was soluble in distilled water in the in-house solubility test and therefore, distilled water was chosen as the vehicle. The 100 pregnant females were randomized into 4 experimental groups containing 25 animals each. The groups, viz., G1, G2, G3 and G4 received 0, 10, 30 and 90 mg/kg bw/day of the test chemical, respectively. The test chemical was administered to these pregnant rats during Gestation Day 5 to 19 at the frequency of once daily. The doses were selected on the basis of previously done, dose range finding study (DRF study). In this study, the test chemical was administered orally to rats in graduated doses of 20, 60 and 180 mg/kg body weight for 14 consecutive days. Mortality was observed in only one animal of 180 mg/kg body weight group, while no mortalities were observed at 20 or 60 mg/kg body weight dose groups. Body weight was affected for both male and female rats of 180 mg/kg body weight dose group, while no change was observed for animals of mid and low dose groups. Further, test chemical related and dose-dependent lesions in stomach and intestine were observed at all the dose groups, which were also confirmed by histopathological analysis. Based on the above stated results, the doses 0, 10, 30 and 90 mg/kg body weight were selected for control, low, mid and high dose groups, respectively in the main study. In this study, all the animals were observed twice daily for any morbidity and/or mortality, throughout the acclimatization and study period. All animals were observed daily for clinical signs and symptoms after dose administration. These observations were regularly performed approximately 1 hour after dose administration, since onset of clinical signs after oral gavage is anticipated in that time frame. Animals were weighed at the time of receipt, on GD 0, on the first day of dosing (GD 5), and on gestation days 8, 11, 14, 17 and 20. The weight of feed provided and that leftover was recorded for each cage on the same day as animal body weight. This data was used to calculate mean feed consumption (g/day/rat) on gestation days 5, 8, 11, 14, 17 and 20. From all dams at termination, blood was collected in the morning; serum was separated and stored under appropriate conditions. All collected blood samples were assessed for serum levels of thyroid hormones (T3 and T4) and thyroid stimulating hormone (TSH) using commercially available Rat ELISA kits. All pregnant females were weighed and euthanized on GD 20 (one day prior to expected day of delivery) by using CO2 asphyxiation. Fetuses were euthanized humanely as per the internal SOP. All animals were subjected to complete gross necropsy. From all dams at termination, thyroid gland were collected, weighed (after fixation) and preserved for histopathological examination. Immediately after the termination, uteri were removed, and the pregnancy status of the animals was evaluated. Uteri that appear non-gravid were further examined using ammonium sulphide staining to confirm non-pregnant status. The total weight of the gravid or non-gravid uteri including cervix were recorded for all animals. Further, the number of corpora lutea and the ovarian and placental weights were determined for all pregnant animals. The uterine contents were also examined for the number of implantation sites, number of live/viable fetuses, number of dead fetuses and number of resorptions. Using the above information, pre-implantation and post-implantation loss was calculated as follows: pre-implantations loss = [(no. of corpora lutea – no. of implantations)/ no. of corpora lutea] x 100 and post-implantation loss = [(no. of implantations – no. of viable fetuses/ no. of implantations] x 100. All fetuses were weighed, sexed and examined for external abnormalities and crown to rump length. For live fetuses, anogenital distances (AGD) were measured. The fetuses were examined for skeletal and soft tissue abnormalities with special emphasis to reproductive organs. Also, male fetuses were evaluated for incomplete testicular descent/cryptorchidism. The one half of each litter were prepared and examined for skeletal abnormalities (growth retardation, delayed ossification, etc.) using Alcian blue and Alizarin red double staining technique and the remainder were prepared for and examined for soft tissue alterations (visceral and head razor sectioning). During observations, no treatment-related clinical signs or symptoms were observed in any of the animals through the study period. No mortality or morbidity was recorded in animals of any of the experimental groups throughout the duration of the experiment. The mean body weight of pregnant and non-pregnant females remained comparable among all the groups for every time point (GD 0, 5, 8, 11, 14, 17 and 20) recorded during the study period. The percent change in body weights with respect to the first day of gestation was also statistically comparable among all the groups of Pregnant and non-pregnant females. Triiodothryronine (T3) and thyroid stimulating hormone (TSH) levels in sera were found to be statistically comparable among the control and treatment groups in both pregnant and non-pregnant females. However, significant decrease in thyroxine (T4) levels were observed in pregnant females of G4 (90 mg/kg) group as compared to G1 (Control) group (P<0.01). Absolute weights and weights relative to body weight of gravid uterus and ovary remained comparable for pregnant females of control and treatment groups. A statistically significant increase was observed in absolute weight of thyroid-parathyroid in pregnant females of G4 group (90 mg/kg) as compared to G1 (control) group (P<0.05). However, when thyroid-parathyroid weights relative to body weights were compared, no significant difference was observed between control and treatment groups. Absolute and relative weights of uterus, ovary, thyroid and parathyroid of non-pregnant females between control and treatment groups remained comparable. The mean feed consumed per day for pregnant females remained statistically equivalent in all groups of pregnant and non-pregnant females. Dams were euthanized and subjected to gross pathology examination. No gross pathological alterations were observed for pregnant and non-pregnant females of control (G1) or treated groups (G2, G3, G4). Thyroid glands from G1 (control) and G4 (90 mg/kg body weight) were subjected to microscopic examination. Congenital cyst (ultimo branchial origin) of thyroid gland was found in 3 animals of each G1 (control) and G4 (90 mg/kg body weight) group. Although congenital cysts were observed for thyroid and parathyroid glands of G4 (90 mg/kg body weight) animals, they were concurrently observed in G1 (Control) group. Furthermore, these cysts are spontaneous in nature and not attributable to the test chemical. No test chemical administration related adverse effect on the pre- and post-implantation losses was observed and remained comparable among all the treatment groups and control group. No significant difference was observed for the mean litter size as there were no significant litter losses by any resorptions across all dose groups. One female from each G1, G2 and G4 had very early resorption which was identified by staining the uterus with ammonium sulphide solution. This effect was no considered as treatment related since it did not have any dose dependent increase and was also observed in the control group. No dead fetuses were observed across all dose groups due to the test chemical administration. No changes in pregnancy duration was observed in all females across all the dose groups due to the test chemical administration. At termination 24/25, 24/25, 24/25 and 21/25 females were found to be pregnant from G1 (control), G2 (10 mg/kg body weight), G3 (30 mg/kg body weight) and G4 (90 mg/kg body weight) group respectively. This effect was not considered to be related to the test chemical administration. The weights of placenta remained comparable for control (G1) and treatment groups (G2, G3 and G4). The mean weight of male foetuses significantly increased in G2 (10 mg/kg body weight) (P<0.01) as compared to G1 (control). Such change in body weight was not observed in other dose groups and therefore it was considered as an incidental finding. There were no dead fetuses and reduction in number of live off springs across all the dose groups due to test chemical administration. No significant changes in the sex ratio of fetuses were observed across all the dose groups due to test chemical administration. No significant changes in the litter sizes and weights were observed across all the dose groups due to test chemical administration. Gross external observation of foetuses revealed that 5.26, 2.08, 2.76 and 7.11 percentage of foetuses from G1 (control), G2 (10 mg/kg), G3 (30 mg/kg) and G4 (90 mg/kg) respectively showed malformations/variations. The variation included haemorrhage in 0.79 percent of foetuses of G4 (90 mg/kg body weight) group and the malformations included: retarded growth (Runt): 3.86 (G1), 2.08 (G2), 2.76 (G3) and 5.93 (G4) percent of fetuses; dome-shaped head (Meningo-encephalocele): 1.4 (G1) and 1.19 (G4) percent of fetuses. No correlation was observed for the doses of the test chemical and the total percent of fetuses with malformations/variations. Similarly, no significant correlation was observed when litter was used as the unit for comparing the malformations/ variations or when data of individual malformations/variations were compared. These observations were found to be independent of the treatment and rather seem to be spontaneous in nature as observed by other studies. Skeletal malformations observed in skull included: hole in skull (mainly in interparietal and occipital region) observed in 5 (1) fetuses (litter) from G1 (Control group) and 3 (1) fetuses (litter) from G4 (90 mg/kg body weight); Bipartite ossification of inter-parietal found in 4 (1) fetuses (litter) from G1 (control) and 3 (1) fetuses (litter) from G4 (90 mg/kg body weight); Bipartite ossification and incomplete ossification of occipital found in 1 fetus from G1 (control) and G4 (90 mg/kg body weight) respectively. Although the number of fetuses with malformations of skull seems to be high, these observations were only present in fetuses of 1 litter each from G1 and G4 group. One rib was absent in 1 fetus from G3 (30 mg/kg body weight) and the same fetus had branched rib; 2 (2), 4 (3), 2 (2) and 2 (1) fetuses (litters) from G1, G2, G3 and G4 respectively showed misaligned ribs. Unossified/incompletely ossified sternebrae were observed in 3 (1), and 2 (1) fetuses (litters) of G1 and G3 respectively; misaligned sternebrae were seen in 1 fetus of G2. Fused cervical vertebrae were observed in 1 fetus of G1. The total percentage of fetuses with skeletal malformations/variations were 6.80, 2.65, 3.36 and 3.76 for G1 (control), G2 (10 mg/kg), G3 (30 mg/kg) and G4 (90 mg/kg) respectively while the percentage of litters affected were found to be 17.39 (G1), 13.04 (G2), 16.67 (G3) and 10.00 (G4). No significant correlation was observed between treatment and individual skeletal malformations/variations or total percentages of fetuses and litters affected. The skeletal malformations/variations noted in treatment group were concurrently seen in control group. Moreover, the occurrence and incidences of these malformations/variations are common in developing fetuses. Therefore, these skeletal developmental malformations/variations were not considered to be test chemical related. In visceral observations, hematoma (ankle of left hind limb) was found in 1 fetus from G2 (10 mg/kg body weight) and enlarged adrenal with reduced thymus size was found in 1 fetus from G3 (30 mg/kg body weight) group. No malformations/variations were observed in any other fetuses of control or treated groups. Head razor examination of fetuses did not show any malformations/variations in control or treated groups. Based on all the available data, it was concluded that there were no test chemical related adverse effects that were observed on the maternal reproductive/developmental toxicity and also fetal parameters. Although, significant decrease in T4 levels in thyroid estimations indicate towards maternal systemic toxicity. Therefore, the LOAEL for maternal systemic toxicity was observed to be 30 mg/kg bw/day, while the NOAEL for the maternal reproductive/developmental toxicity and fetal developmental toxicity was observed to be 90 mg/kg bw/day.
Therefore, based on all the available data from the above study, it was concluded that the test chemical did not show any adverse effects on maternal reproductive/developmental toxicity and fetal parameters and is not likely to be classified as 'reproductive and developmental toxicant' as per the CLP criteria of classification and labelling.
Justification for classification or non-classification
Based on all the available data, it was concluded that the test chemical did not show any adverse effects on maternal reproductive/developmental toxicity and fetal parameters and is not likely to be classified as 'reproductive and developmental toxicant' as per the CLP criteria of classification and labelling.
Additional information
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.